Human immunodeficiency virus type–1 (HIV-1) manipulates fundamental host cell
processes in sophisticated ways to achieve optimum replicative efficiency. Recent studies …

The past 3 years have witnessed the spectacular irruption of lentiviral vectors into the
limelight of the gene therapy scene. Owing to their ability to deliver transgenes in tissues that …

The human immunodeficiency virus type 1 (HIV-1) encodes a protein, called Vpr, that
prevents proliferation of infected cells by arresting them in G2 of the cell cycle. This Vpr …

The human SAMHD1 protein potently restricts lentiviral infection in dendritic cells and
monocyte/macrophages but is antagonized by the primate lentiviral protein Vpx, which …

HIV up-regulates cell-surface expression of specific ligands for the activating NKG2D
receptor, including ULBP-1,-2, and-3, but not MICA or MICB, in infected cells both in vitro …

African green monkeys can maintain long-term persistent infection with simian
immunodeficiency viruses (SIVagm) without developing AIDS and thus provide an important …

Like other HIV-1 auxiliary proteins, Vpr is conserved within all the human (HIV-1, HIV-2) and
simian (SIV) immunodeficiency viruses. However, Vpr and homologous HIV-2, and SIV Vpx …

The expression levels of∼ 4,600 cellular RNA transcripts were assessed in CD4+-T-cell
lines at different times after infection with human immunodeficiency virus type 1 strain BRU …

Recent commercialization of lentiviral vector (LV)-based cell therapies and successful
reports of clinical studies have demonstrated the untapped potential of LVs to treat diseases …

The viral accessory protein Vpx is required for productive in vitro infection of macrophages
by simian immunodeficiency virus from sooty mangabey monkeys (SIV SM). To evaluate the …